The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

Documenti analoghi

• The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
  di: Shroff, Rachna T, et al.
  Pubblicazione: (2017)
• Phase Ib/II study of the safety and efficacy of combination therapy with multikinase vascular endothelial growth factor inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma
  di: Subbiah, Vivek, et al.
  Pubblicazione: (2017)
• A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
  di: Kurzrock, Razelle, et al.
  Pubblicazione: (2019)
• Trametinib: a MEK inhibitor for management of metastatic melanoma
  di: Lugowska, Iwona, et al.
  Pubblicazione: (2015)
• Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
  di: Caruana, Marco, et al.
  Pubblicazione: (2020)